Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Free Research Reports on ANAC, KERX, LXK and PFE Issued by the Bedford Report Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT


Print article Print article
© Marketwire 2013
2013-01-30 14:25:38 -

NEW YORK, NY -- (Marketwire) -- 01/30/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.



Anacor Pharmaceuticals Inc. (NASDAQ: ANAC) shares plummeted over 20 percent on nearly 5 million shares traded Tuesday. On Tuesday, the company reported positive preliminary results from the first of two Phase 3 trials of tavaborole, its topical anti-fungal for onychomycosis.



Find out more about Anacor Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ANAC : www.bedfordreport.com/ANAC





Keryx Biopharmaceuticals (NASDAQ: KERX) shares soared over 40 percent on nearly 12-times the average daily volume Tuesday. The company has reported that Zerenex, its treatment for kidney failure, met primary and all key secondary endpoints in a recent Phase 3 study.



Find out more about Keryx Biopharmaceuticals including full access to the free equity report at: www.BedfordReport.com/KERX : www.bedfordreport.com/KERX



Lexmark International Inc. (NYSE: LXK) shares declined 15 percent on four-times the average daily volume Tuesday. The company reported GAAP earnings per share for the fourth quarter of 2012 were $0.10, a decline of 91 percent when compared to the year ago quarter.



Find out more about Lexmark International including full access to the free equity report at: www.BedfordReport.com/LXK : www.bedfordreport.com/LXK



Pfizer Inc. (NYSE: PFE) shares spiked over 3 percent on more than 41 million shares traded Tuesday. The major drug manufacturer reported a net income of $6.32 million in the fourth quarter, compared to a net income of $1.44 billion in the year ago quarter. The company's strong results were due largely to its sale of its nutrition business to Nestle.



Find out more about Pfizer including full access to the free equity report at: www.BedfordReport.com/PFE : www.bedfordreport.com/PFE



Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.



A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.




Contact Information:

Equity News Circuit
Email Contact : www2.marketwire.com/mw/emailprcntct?id=307343BCE2AA8DFF



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com